[The results of immunotherapy as an adjunct to the surgical treatment of primary lung cancers].
A total of 263 primary non-small cell lung cancer patients resected in our Institute from March, 1978 to October, 1984 were utilized in order to evaluate the efficacy of transfer factor (TF) immunotherapy as an adjunct to surgical treatment and TF was significantly effective to cases with stage I diseases, but not to stages II, III and IV diseases, indicating that TF could only suppressed micrometastasis existing at the time of surgery. In order to improve the further results of immunotherapy as an adjunct to surgical treatment, we analyzed cytotoxic activity against autologous lung cancer and K562 leukemia cells in tumor bearing hosts. Furthermore, we studied the effect of interleukin 2 (IL2) activated lymphocyte dialysate on cytotoxic activity against lung cancer cells. When 3 different sources of lymphocytes including peripheral blood lymphocytes (PBL) regional lymphnode cells (LNC) and tumor infiltrating lymphocytes (TIL) were incubated with IL2 for 8 days at 37 degrees C in 5% CO2 atmosphere, relatively high cytotoxic activity was demonstrated with 2 major different patterns in PBL, LNC and TIL including one systemic predominant and the other local predominant patterns, suggesting that IL2 might be a local or systemic possible immunotherapeutic reagent. Finally, we stimulated lymphocytes from household contact family members with IL2 and MMC treated lung cancer cells. These in vitro modulated T-lymphocytes demonstrated considerable cytotoxic activity against the target cells which were used as in vitro sensitization. The dialysate of these in vitro stimulated cells showed specific activity on cytotoxicity against lung cancer cells and might be a possible reagent in stead of TF for clinical trial.